Outlook Therapeutics Inc
NASDAQ:OTLK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bindi Metals Ltd
ASX:BIM
|
AU |
|
T
|
Trident Texofab Ltd
BSE:540726
|
IN |
|
Itau Unibanco Holding SA
BOVESPA:ITUB4
|
BR |
|
Companhia Estadual de Distribuicao de Energia Eletrica CEEED
BOVESPA:CEED4
|
BR |
|
DWS Group GmbH & Co KgaA
XETRA:DWS
|
DE |
|
H
|
Hsin Kuang Steel Co Ltd
TWSE:2031
|
TW |
|
Preferred Bank
NASDAQ:PFBC
|
US |
|
M
|
Mawana Sugars Ltd
NSE:MAWANASUG
|
IN |
|
R
|
Rockworth PCL
SET:ROCK
|
TH |
|
Tata Communications Ltd
NSE:TATACOMM
|
IN |
|
C
|
Coloplast A/S
OTC:CLPBY
|
DK |
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Outlook Therapeutics Inc
NASDAQ:OTLK
|
16.7m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
184.6B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.3B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Outlook Therapeutics Inc
Glance View
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 9 full-time employees. The company went IPO on 2016-06-13. The firm focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. ONS-5010, is the Company's product candidate, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. Its clinical program for ONS-5010 in wet AMD involves three clinical trials, which includes NORSE ONE, NORSE TWO and NORSE THREE. Outlook sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets for the treatment of wet AMD, diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Outlook Therapeutics Inc is -19 811.4%, which is below its 3-year median of -9 793.4%.
Over the last 7 months, Outlook Therapeutics Inc’s Operating Margin has decreased from -4 824.6% to -19 811.4%. During this period, it reached a low of -19 811.4% on Jan 31, 2026 and a high of -4 744.4% on Sep 30, 2025.
